Strand has developed the first platform for the creation of programmable, long-acting mRNA therapeutics capable of delivering multi-functional treatments for deadly diseases, with an initial aim of ...
Messenger RNA brought the world its first Covid-19 vaccines, demonstrating along the way how this technology works. Strand Therapeutics is developing what could become the next generation of mRNA ...
BOSTON--(BUSINESS WIRE)--Strand Therapeutics, the world’s first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first patient ...
For many, mRNA-based medicines are synonymous with COVID-19 vaccines, but vaccination is just the tip of the iceberg for the technology. Strand Therapeutics is one of the companies looking below the ...
-- Financing oversubscribed; proceeds from the round will be used to expand Strand’s growing mRNA platforms into multiple immuno-oncology and disease settings, and advance lead drug into Phase 1 ...
An impressive array of Big Pharma backers lined up to ensure Strand Therapeutics has the funding needed to take its mRNA-based solid tumor drug further into the clinic. New Strand supporters that ...
As the first vaccines for Covid-19 rolled out at the end of 2020, messenger RNA catapulted into public awareness. Now, a few years later, interest in mRNA has exploded. Clinical trials are underway ...
Strand Therapeutics has added to its series A funding from last year, bringing the total to $97 million. The messenger RNA (mRNA) therapeutics company is gearing up to bring its lead drug candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback